康缘药业: 江苏康缘药业股份有限公司监事会关于回购注销公司2022年度限制性股票激励计划剩余全部限制性股票相关事项的核查意见

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. will repurchase and cancel all remaining restricted stocks from the 2022 stock incentive plan due to unmet performance targets for the year 2024 [1][2] Group 1 - The company will repurchase and cancel 3.3003 million shares of restricted stock granted to 155 incentive recipients as part of the 2022 stock incentive plan [1][2] - The repurchase and cancellation of the restricted stocks comply with relevant regulations and the company's incentive plan [2] - The decision has undergone the necessary review procedures, and the reasons, quantity, and price for the repurchase are deemed reasonable and legal [2]